ZEFIT is a company that uses zebrafish as an early in-vivo testing model to analyze and assess new compounds, providing rapid and reliable results. They offer compound testing services to research institutes and pharmaceutical companies, using AI-based lab infrastructure to optimize drug development Platform and accelerate commercialization. The company uses zebrafish for early in vivo testing, reducing reliance on traditional animal models. The rapid life cycle of zebrafish allows for high-throughput screening, accelerating research drug approval process. Zefit’s platform combines biologists and AI technology specialists to to shorten drug development process from bench to preclinic. Zefit has offered drug candidate testing services to more than 65 research institutes and pharmaceutical companies, favoring their innovation.
Drug Development Platform:
- ZEFIT offers advanced compound testing solutions for drug development, utilizing AI-driven efficiency and precision, reducing testing time and data discrepancy.
- The experts create customized zebrafish disease models using genome editing, ensuring optimal conditions for development and maintenance in dedicated and certified facilities.
- The experimental infrastructure utilizes advanced AI technology to improve testing speed, data reliability, and precision, reducing variability and ensuring consistent results.
- Zefit’s large scale in-vivo data can provide precise predictions of drug toxicity and efficacy, aiding in the optimization of drug candidates for further development and commercialization.
- The revolutionizing drug discovery by combining advanced biotechnology with AI, resulting in faster and more effective treatments.
If you are looking for a high-throughput drug discovery platform in vertebrates, you can find relevant information at ZEFIT.
For more information, please visit zefit.co.kr/en.
View More: Preclinical Research Services for Drug Discovery
